SEPNNasdaqPharmaceutical PreparationsFiscal year ends December 31

Septerna, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026

$36.38+0.03 (+0.08%)

Close on Oct 19, 2026

Market cap: $1.64B
P/E (TTM): –
Dividend yield: –

Septerna, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31
Revenue	46	1.08	0.15
Research & Development	98	65	36
General & Administrative	29	17	9.72
Operating Expenses	114	82	-1.92
Operating Income	-68	-81	2.08
Interest & Investment Income	20	8.62	2.79
Other Non-Operating Income	19	8.53	2.80
Gain (Loss) on Sale of Assets	13	0	48
Pretax Income	-49	-72	-49
Income Tax Expense	0.01	-0.50	0.69
Net Income incl. Noncontrolling Interests	-49	-72	4.18
Net Income	-49	-72	4.18
Net Income to Common	–	-72	0.57
EPS (Basic)(per share)	-1.10	-7.26	0.29
EPS (Diluted)(per share)	-1.10	-7.26	0.29
Shares Outstanding (Basic, Weighted)(shares)	44	9.89	1.93
Shares Outstanding (Diluted, Weighted)(shares)	44	9.89	2.18
EBITDA	-67	-79	2.88

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -44.0%
Net margin: -24.5%
Return on equity, FY2025: -12.2%

Financial strength

Current ratio: 4.99
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 106.7%

Valuation

P/E ratio: –
Price to sales: 16.57
Price to book: 4.24
Dividend yield: –